KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Net Income towards Common Stockholders rose 5422.3% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 13793.64%. This contributed to the annual value of -$116.9 million for FY2024, which is 3916.16% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Net Income towards Common Stockholders of $18.1 million as of Q3 2025, which was up 5422.3% from $35.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $35.6 million during Q2 2025, with a 5-year trough of -$120.8 million in Q2 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$2.2 million (2022), whereas its average is -$10.5 million.
  • Over the last 5 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders had its largest YoY gain of 46005.95% in 2023, and its largest YoY loss of 217669.05% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$6.4 million in 2021, then soared by 32.05% to -$4.3 million in 2022, then crashed by 2176.69% to -$98.6 million in 2023, then soared by 78.94% to -$20.8 million in 2024, then soared by 187.26% to $18.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at $18.1 million for Q3 2025, versus $35.6 million for Q2 2025 and $24.6 million for Q1 2025.